8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
May 1, 2026·SEC
Atara Biotherapeutics, Inc.(ATRA)Earnings, Financials & Key Ratios
ATRA•NASDAQ
3.9× P/E·Price updated Jun 19, 2026
AboutAtara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Show more
- Revenue$121M-6.3%
- EBITDA$38M+148.4%
- Net Income$33M+138.3%
- EPS (Diluted)2.57+122.5%
- Gross Margin82.44%-1.5%
- EBITDA Margin31.45%+151.7%
- Operating Margin29.69%+145.9%
- Net Margin27.07%+140.9%
ATRA Key Insights
Atara Biotherapeutics, Inc. (ATRA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 90 (top 10%)
- ✓Efficient asset utilization: 6.0x turnover
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 69.8% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ATRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ATRA Price & Volume
Atara Biotherapeutics, Inc. (ATRA) stock price & volume — 10-year historical chart
Loading chart...
ATRA Growth Metrics
Atara Biotherapeutics, Inc. (ATRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years23.85%
TTM-88.41%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM39.47%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM81.99%
Return on Capital
10 Years0.29%
5 Years84.85%
3 Years251.45%
Last Year674.99%
ATRA Recent Earnings
Atara Biotherapeutics, Inc. (ATRA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.29+12.0%
$0.33
Rev
$516,000-82.2%
$3M
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.25-177.8%
$0.09
Rev
$2M-51.2%
$3M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.32+61.4%
$0.83
Rev
$3M+393.3%
$700,000
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.19+159.4%
$0.32
Rev
$18M+876.4%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.29vs $0.33+12.0% | $516,000vs $3M-82.2% |
| Q2 2026 | Mar 16, 2026 | $0.25vs $0.09-177.8% | $2Mvs $3M-51.2% |
| Q4 2025 | Nov 12, 2025 | $0.32vs $0.83+61.4% | $3Mvs $700,000+393.3% |
| Q3 2025 | Aug 11, 2025 | $0.19vs $0.32+159.4% | $18Mvs $2M+876.4% |
Based on last 12 quarters of dataView full earnings history →
ATRA Peer Comparison
Atara Biotherapeutics, Inc. (ATRA) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 ADCT | 138.64M | 1.09 | -0.97 | 14.85% | -173.02% | |||
 CABA | 463.08M | 2.84 | -1.73 | -131.58% | 0.24 | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 |
Compare ATRA vs Peers
Atara Biotherapeutics, Inc. (ATRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ATRA Income Statement
Atara Biotherapeutics, Inc. (ATRA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 20.34M | 63.57M | 8.57M | 128.94M | 120.77M | 23.14M |
Revenue Growth % | - | - | - | - | - | 212.55% | -86.51% | 1404.02% | -6.33% | -88.41% |
Cost of Goods Sold | 956K | 3.78M | 0 | 244.65M | 282M | 0 | 8.89M | 21.01M | 21.21M | 897K |
COGS % of Revenue | - | - | - | - | 1386.44% | - | 103.65% | 16.29% | 17.56% | - |
Gross Profit | -956K▲ 0% | -3.78M▼ 295.5% | 0▲ 100.0% | -244.65M▲ 0% | -261.66M▼ 7.0% | 63.57M▲ 124.3% | -313K▼ 100.5% | 107.93M▲ 34582.7% | 99.56M▼ 7.8% | 22.24M▲ 0% |
Gross Margin % | - | - | - | - | -1286.44% | 100% | -3.65% | 83.71% | 82.44% | 96.12% |
Gross Profit Growth % | -149.61% | -295.5% | 100% | - | -6.95% | 124.3% | -100.49% | 34582.75% | -7.76% | - |
Operating Expenses | 121.53M | 237.11M | 295.68M | 64.4M | 78.8M | 344.09M | 275.69M | 191.37M | 63.7M | 28.55M |
OpEx % of Revenue | - | - | - | - | 387.42% | 541.25% | 3215.83% | 148.42% | 52.74% | - |
Selling, General & Admin | 40.33M | 69.65M | 79.58M | 64.4M | 78.8M | 71.55M | 50.91M | 39.89M | 26.25M | 17.8M |
SG&A % of Revenue | - | - | - | - | 387.42% | 112.55% | 593.82% | 30.93% | 21.74% | - |
Research & Development | 81.21M | 167.46M | 216.1M | 244.65M | 282M | 272.53M | 224.78M | 151.48M | 37.45M | 10.18M |
R&D % of Revenue | - | - | - | - | 1386.44% | 428.69% | 2622.01% | 117.48% | 31% | - |
Other Operating Expenses | 0 | 0 | 0 | -244.65M | -282M | 0 | 0 | 0 | 0 | 579K |
Operating Income | -121.53M▲ 0% | -237.11M▼ 95.1% | -295.68M▼ 24.7% | -309.05M▼ 4.5% | -340.46M▼ 10.2% | -280.51M▲ 17.6% | -276.01M▲ 1.6% | -83.44M▲ 69.8% | 35.86M▲ 143.0% | -6.31M▲ 0% |
Operating Margin % | - | - | - | - | -1673.85% | -441.25% | -3219.48% | -64.71% | 29.69% | -27.27% |
Operating Income Growth % | -49.59% | -95.1% | -24.7% | -4.52% | -10.16% | 17.61% | 1.61% | 69.77% | 142.98% | - |
EBITDA | -120.58M | -233.33M | -288.54M | -300.72M | -331.12M | -274.86M | -271.18M | -78.39M | 37.98M | -5.96M |
EBITDA Margin % | - | - | - | - | -1627.91% | -432.35% | -3163.15% | -60.79% | 31.45% | -25.75% |
EBITDA Growth % | -49.12% | -93.51% | -23.66% | -4.22% | -10.11% | 16.99% | 1.34% | 71.09% | 148.45% | 24.89% |
D&A (Non-Cash Add-back) | 956K | 3.78M | 7.14M | 8.33M | 9.35M | 5.65M | 4.83M | 5.05M | 2.12M | 350K |
EBIT | -121.53M | -237.11M | -295.68M | -309.05M | -340.46M | -227.92M | -270.83M | -80.8M | 36.51M | -5.88M |
Net Interest Income | 0 | 0 | 0 | 0 | 367K | 2.69M | 141K | -2.5M | -3.11M | -3.1M |
Interest Income | 2.03M | 6.37M | 0 | 0 | 367K | 3.06M | 5.43M | 2.11M | 683K | 501K |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 373K | 5.29M | 4.62M | 3.79M | 3.6M |
Other Income/Expense | 2.03M | 6.37M | 4.72M | 2.45M | 367K | 52.22M | -105K | -1.98M | -3.14M | -3.13M |
Pretax Income | -119.5M▲ 0% | -230.74M▼ 93.1% | -290.96M▼ 26.1% | -306.61M▼ 5.4% | -340.1M▼ 10.9% | -228.29M▲ 32.9% | -276.11M▼ 20.9% | -85.42M▲ 69.1% | 32.72M▲ 138.3% | -9.44M▲ 0% |
Pretax Margin % | - | - | - | - | -1672.05% | -359.1% | -3220.7% | -66.24% | 27.09% | -40.78% |
Income Tax | -14K | -44K | 12K | 15K | 46K | 12K | 15K | -12K | 31K | 31K |
Effective Tax Rate % | 0.01% | 0.02% | -0% | -0% | -0.01% | -0.01% | -0.01% | 0.01% | 0.09% | -0.33% |
Net Income | -1.19B▲ 0% | -2.31B▼ 93.1% | -290.98M▲ 87.4% | -306.62M▼ 5.4% | -340.14M▼ 10.9% | -228.3M▲ 32.9% | -276.13M▼ 20.9% | -85.4M▲ 69.1% | 32.69M▲ 138.3% | -9.47M▲ 0% |
Net Margin % | - | - | - | - | -1672.28% | -359.12% | -3220.88% | -66.23% | 27.07% | -40.91% |
Net Income Growth % | -51.16% | -93.07% | 87.39% | -5.38% | -10.93% | 32.88% | -20.95% | 69.07% | 138.28% | 39.47% |
Net Income (Continuing) | -119.49M | -230.7M | -290.98M | -306.62M | -340.14M | -228.3M | -276.13M | -85.4M | 32.69M | -9.47M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -100.03▲ 0% | -131.64▼ 31.6% | -141.78▼ 7.7% | -103.63▲ 26.9% | -90.78▲ 12.4% | -55.96▲ 38.4% | -65.18▼ 16.5% | -11.41▲ 82.5% | 2.57▲ 122.5% | -0.67▲ 0% |
EPS Growth % | -45.43% | -31.6% | -7.7% | 26.91% | 12.4% | 38.36% | -16.48% | 82.49% | 122.52% | 81.99% |
EPS (Basic) | -100.03 | -131.64 | -141.78 | -103.63 | -90.78 | -55.96 | -65.18 | -11.41 | 2.61 | - |
Diluted Shares Outstanding | 1.19M | 1.75M | 2.05M | 2.96M | 3.75M | 4.08M | 4.24M | 7.49M | 12.72M | 14.08M |
Basic Shares Outstanding | 1.19M | 1.75M | 2.05M | 2.96M | 3.75M | 4.08M | 4.24M | 7.49M | 12.54M | 14.08M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ATRA Balance Sheet
Atara Biotherapeutics, Inc. (ATRA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 172.19M | 321.49M | 272.99M | 523.27M | 384.62M | 295.08M | 101.87M | 64.89M | 12.21M | 12.17M |
Cash & Short-Term Investments | 166.1M | 309.63M | 259.11M | 500.66M | 371.07M | 242.82M | 51.73M | 42.5M | 8.48M | 8.36M |
Cash Only | 79.22M | 60.7M | 74.32M | 200.4M | 106.08M | 92.94M | 25.84M | 25.03M | 8.48M | 8.36M |
Short-Term Investments | 86.87M | 248.93M | 184.79M | 300.25M | 264.98M | 149.88M | 25.88M | 17.47M | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 1.25M | 986K | 40.22M | 34.11M | 1.48M | 1.25M | 0 |
Days Sales Outstanding | - | - | - | - | 17.69 | 230.93 | 1.45K | 4.2 | 3.79 | 12.49 |
Inventory | 0 | 0 | 0 | 0 | 0 | 1.59M | 9.71M | 10.65M | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | 398.68 | 185.11 | - | - |
Other Current Assets | 194K | 194K | 194K | 194K | 194K | 10.45M | 6.33M | 10.26M | 2.48M | 3.81M |
Total Non-Current Assets | 45.59M | 70.35M | 69.95M | 64.85M | 83.51M | 81.34M | 63.63M | 44.2M | 8.02M | 7.82M |
Property, Plant & Equipment | 44.13M | 68.58M | 68.18M | 62.82M | 79.94M | 74.32M | 58.79M | 41.1M | 7.14M | 6.93M |
Fixed Asset Turnover | - | - | - | - | 0.25x | 0.86x | 0.15x | 3.14x | 16.92x | 2.56x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 1.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 1.46M | 574K | 1.77M | 2.03M | 3.57M | 7.02M | 4.84M | 3.1M | 886K | 890K |
Total Assets | 217.78M▲ 0% | 391.84M▲ 79.9% | 342.94M▼ 12.5% | 588.12M▲ 71.5% | 468.13M▼ 20.4% | 376.42M▼ 19.6% | 165.5M▼ 56.0% | 109.1M▼ 34.1% | 20.23M▼ 81.5% | 20M▲ 0% |
Asset Turnover | - | - | - | - | 0.04x | 0.17x | 0.05x | 1.18x | 5.97x | 0.86x |
Asset Growth % | -17.48% | 79.93% | -12.48% | 71.49% | -20.4% | -19.59% | -56.03% | -34.08% | -81.45% | -296.62% |
Total Current Liabilities | 27.65M | 39.98M | 36.74M | 82.9M | 105.79M | 78.92M | 142.23M | 134.57M | 14.92M | 5.64M |
Accounts Payable | 14.71M | 3.72M | 7.96M | 7.12M | 17.37M | 6.87M | 3.68M | 4.37M | 127K | 637K |
Days Payables Outstanding | 5.62K | 359.01 | - | 10.62 | 22.48 | - | 151.32 | 75.87 | 2.19 | 289.31 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.78M | 0 |
Deferred Revenue (Current) | 0 | -490K | 0 | 33.45M | 40.76M | 8M | 77.83M | 95.09M | 716K | 4.02M |
Other Current Liabilities | 500K | 0 | 14.71M | 19.89M | 25.15M | 32.75M | 37.01M | 6.59M | 3.3M | 4.32M |
Current Ratio | 6.23x | 8.04x | 7.43x | 6.31x | 3.64x | 3.74x | 0.72x | 0.48x | 0.82x | 2.16x |
Quick Ratio | 6.23x | 8.04x | 7.43x | 6.31x | 3.64x | 3.72x | 0.65x | 0.40x | 0.82x | 2.16x |
Cash Conversion Cycle | - | - | - | - | - | - | 1.7K | 113.44 | - | -276.83 |
Total Non-Current Liabilities | 12.27M | 13M | 15.42M | 42.88M | 82.73M | 170.86M | 122.51M | 71.81M | 43.81M | 51.66M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32.67M | 9.08M |
Capital Lease Obligations | 0 | 0 | 14.14M | 13.04M | 25.52M | 58.06M | 45.69M | 29.91M | 9.35M | 39.78M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 12.27M | 13M | 1.28M | 2.04M | 1.5M | 35.8M | 39.25M | 41.89M | 1.79M | 42.59M |
Total Liabilities | 39.91M | 52.98M | 52.16M | 125.78M | 188.51M | 249.78M | 264.74M | 206.38M | 58.74M | 57.31M |
Total Debt | 0 | 738K | 15.72M | 15.03M | 28.27M | 71.7M | 57.87M | 43.83M | 52.8M | 9.08M |
Net Debt | -79.22M | -59.96M | -58.6M | -185.38M | -77.81M | -21.24M | 32.03M | 18.8M | 44.32M | 716K |
Debt / Equity | - | 0.00x | 0.05x | 0.03x | 0.10x | 0.57x | - | - | - | -0.24x |
Debt / EBITDA | - | - | - | - | - | - | - | - | 1.39x | -1.52x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 1.17x | -0.12x |
Interest Coverage | - | - | - | - | - | -611.04x | -51.24x | -17.51x | 9.63x | -1.63x |
Total Equity | 177.86M▲ 0% | 338.86M▲ 90.5% | 290.78M▼ 14.2% | 462.34M▲ 59.0% | 279.61M▼ 39.5% | 126.64M▼ 54.7% | -99.23M▼ 178.4% | -97.28M▲ 2.0% | -38.5M▲ 60.4% | -37.31M▲ 0% |
Equity Growth % | -29.9% | 90.51% | -14.19% | 59% | -39.52% | -54.71% | -178.36% | 1.96% | 60.42% | 220.6% |
Book Value per Share | 148.90 | 193.36 | 141.68 | 156.25 | 74.63 | 31.04 | -23.42 | -12.99 | -3.03 | -2.65 |
Total Shareholders' Equity | 177.86M | 338.86M | 290.78M | 462.34M | 279.61M | 126.64M | -99.23M | -97.28M | -38.5M | -37.31M |
Common Stock | 3K | 5K | 6K | 8K | 9K | 10K | 11K | 1K | 1K | 1K |
Retained Earnings | -296.65M | -527.35M | -817.96M | -1.12B | -1.46B | -1.69B | -1.97B | -2.05B | -2.02B | -2.03B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -151K | -340K | 220K | 296K | -368K | -2.07M | -204K | 8K | 1K | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ATRA Cash Flow Statement
Atara Biotherapeutics, Inc. (ATRA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -87.5M | -179.77M | -235.63M | -180.76M | -220.52M | -270.43M | -192.98M | -68.72M | -50.94M | -25.88M |
Operating CF Margin % | - | - | - | - | -1084.18% | -425.38% | -2250.99% | -53.29% | -42.18% | - |
Operating CF Growth % | -45.78% | -105.45% | -31.07% | 23.29% | -22% | -22.63% | 28.64% | 64.39% | 25.87% | 51.7% |
Net Income | -119.49M | -230.7M | -290.98M | -306.62M | -340.14M | -228.3M | -276.13M | -85.4M | 32.69M | -9.47M |
Depreciation & Amortization | 956K | 3.73M | 7.07M | 8.33M | 9.35M | 5.65M | 4.83M | 5.05M | 2.38M | 175K |
Stock-Based Compensation | 23.1M | 33.82M | 51.7M | 51.35M | 53.87M | 53.84M | 45.39M | 27M | 9.75M | 5.54M |
Deferred Taxes | 0 | -1.89M | 0 | 958K | 1.79M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 732K | 260K | 732K | 1.53M | 2.04M | -40.15M | 17.59M | 15.59M | 8.98M | 81.39M |
Working Capital Changes | 7.2M | 15M | -4.15M | 63.69M | 52.58M | -61.47M | 15.34M | -30.96M | -104.73M | -103.52M |
Change in Receivables | 0 | 0 | 0 | -1.25M | 264K | -39.23M | 6.11M | 32.63M | 229K | 8.88M |
Change in Inventory | 0 | 0 | 0 | -1.25M | 3.34M | -1.59M | -8.12M | -4.43M | 10.65M | 0 |
Change in Payables | 2.16M | -1.96M | 4.21M | -815K | 9.07M | -9.21M | -3.13M | 687K | -4.24M | -747K |
Cash from Investing | 98.71M | -196.29M | 60.46M | -120.73M | 22.26M | 202.96M | 123.87M | 8.62M | 18.15M | 949K |
Capital Expenditures | -20.23M | -35.92M | -5.73M | -4.51M | -10.58M | -4.19M | -1.22M | -246K | 0 | 349K |
CapEx % of Revenue | - | - | - | - | 52.02% | 6.6% | 14.27% | 0.19% | - | 1.51% |
Acquisitions | 0 | 0 | 0 | 116.22M | -32.84M | 0 | 0 | 0 | 948K | 44K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -1.2M | -160.36M | 161K | -116.22M | 32.84M | 94.77M | 25K | 0 | 0 | -4.86M |
Cash from Financing | 20.05M | 357.54M | 188.79M | 427.57M | 103.94M | 53.08M | 2.01M | 59.28M | 16.1M | 19.3M |
Debt Issued (Net) | 0 | -528K | -486K | -389K | -254K | -518K | -947K | -892K | -250K | 0 |
Equity Issued (Net) | 19.16M | 340.88M | 188.62M | 422.97M | 98.7M | 21.89M | 2.14M | 59.95M | 16.35M | 3.99M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 892K | 17.19M | 655K | 4.99M | 5.5M | 31.71M | 821K | 223K | -1K | 15.31M |
Net Change in Cash | 31.25M▲ 0% | -18.52M▼ 159.3% | 13.62M▲ 173.5% | 126.09M▲ 825.8% | -94.32M▼ 174.8% | -14.39M▲ 84.7% | -67.1M▼ 366.3% | -811K▲ 98.8% | -16.69M▼ 1958.4% | -5.63M▲ 0% |
Free Cash Flow | -107.73M▲ 0% | -215.7M▼ 100.2% | -241.36M▼ 11.9% | -185.27M▲ 23.2% | -231.1M▼ 24.7% | -274.62M▼ 18.8% | -194.2M▲ 29.3% | -68.96M▲ 64.5% | -50.94M▲ 26.1% | -25.88M▲ 0% |
FCF Margin % | - | - | - | - | -1136.19% | -431.98% | -2265.25% | -53.48% | -42.18% | -111.82% |
FCF Growth % | -70.88% | -100.21% | -11.9% | 23.24% | -24.74% | -18.83% | 29.28% | 64.49% | 26.13% | 61.59% |
FCF per Share | -90.19 | -123.08 | -117.60 | -62.61 | -61.68 | -67.32 | -45.84 | -9.21 | -4.01 | -1.84 |
FCF Conversion (FCF/Net Income) | 0.07x | 0.08x | 0.81x | 0.59x | 0.65x | 1.18x | 0.70x | 0.80x | -1.56x | 2.73x |
Interest Paid | 0 | 0 | 50K | 62K | 32K | 335K | 447K | 685K | 0 | 105K |
Taxes Paid | 0 | 0 | 0 | 10K | 15K | 19K | 2K | 24K | 0 | 31K |
ATRA Key Ratios
Atara Biotherapeutics, Inc. (ATRA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -553.71% | -892.93% | -92.43% | -81.43% | -91.69% | -112.39% | -2014.86% | - | - | 25.68% |
Return on Invested Capital (ROIC) | -59.89% | -94.21% | -86.78% | -91.05% | -106.67% | -136.97% | -1083.74% | - | 462.62% | 38.76% |
Gross Margin | - | - | - | - | -1286.44% | 100% | -3.65% | 83.71% | 82.44% | 96.12% |
Net Margin | - | - | - | - | -1672.28% | -359.12% | -3220.88% | -66.23% | 27.07% | -40.91% |
Debt / Equity | - | 0.00x | 0.05x | 0.03x | 0.10x | 0.57x | - | - | - | -0.24x |
Interest Coverage | - | - | - | - | - | -611.04x | -51.24x | -17.51x | 9.63x | -1.63x |
FCF Conversion | 0.07x | 0.08x | 0.81x | 0.59x | 0.65x | 1.18x | 0.70x | 0.80x | -1.56x | 2.73x |
Revenue Growth | - | - | - | - | - | 212.55% | -86.51% | 1404.02% | -6.33% | -88.41% |
Related:ATRA Dividend History·ATRA Revenue History·ATRA Price History·ATRA P/E History·ATRA Financial Ratios·ATRA Institutional Holders
ATRA SEC Filings & Documents
Atara Biotherapeutics, Inc. (ATRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
ATRA Frequently Asked Questions
Atara Biotherapeutics, Inc. (ATRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Atara Biotherapeutics, Inc. (ATRA) reported $23.1M in revenue for fiscal year 2025.
Atara Biotherapeutics, Inc. (ATRA) saw revenue decline by 6.3% over the past year.
Atara Biotherapeutics, Inc. (ATRA) reported a net loss of $9.5M for fiscal year 2025.
Dividend & Returns
Atara Biotherapeutics, Inc. (ATRA) had negative free cash flow of $25.9M in fiscal year 2025, likely due to heavy capital investments.